News SpliceBio gathers $135m for eye disease gene therapies Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.
News World first as infant gets personalised CRISPR therapy In a medical breakthrough, a child diagnosed with a rare genetic disorder has received a bespoke CRISPR gene editing therapy to correct the mutation.
News Beam launches $500m financing on base-editing trial data Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward.
News Sickle cell gene therapy Casgevy finally cleared for NHS use Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.
News CRISPR biotech Intellia cuts staff as it eyes 2027 launch Eyeing a first commercial launch in 2027, Intellia is re-prioritising by cutting 27% of its workforce and shelving a lung disease candidate.
News Editas axes two-thirds of its staff, including its CMO Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.
News MSD aims to plug dengue fever vaccine gap in US MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face